Humanistic and economic burden associated with depression in the United States: a cross-sectional survey analysis.
Anxiety
Depression
Healthcare resource utilization
Quality of life
Sleep disorder
Work productivity
Journal
BMC psychiatry
ISSN: 1471-244X
Titre abrégé: BMC Psychiatry
Pays: England
ID NLM: 100968559
Informations de publication
Date de publication:
11 08 2022
11 08 2022
Historique:
received:
28
01
2022
accepted:
25
07
2022
entrez:
11
8
2022
pubmed:
12
8
2022
medline:
16
8
2022
Statut:
epublish
Résumé
Depression (major depressive disorder [MDD]) affects the functioning of patients in many facets of life. Very few large-scale studies to date have compared health and economic related outcomes of those with versus without depression, and across various depression severity groups. We aimed to evaluate humanistic and economic burden in respondents with and without depression diagnosis, and across symptom severity groups. Data from the 2017 US National Health and Wellness Survey (NHWS) were utilized. Of the adult respondents (N = 75,004), 59,786 were < 65 years old. Respondents not meeting eligibility criteria were excluded (e.g., those self-reporting bipolar disorder or experiencing depression in past 12 months but no depression diagnosis). Overall, data from 39,331 eligible respondents (aged 18-64 years) were analyzed; and comprised respondents 'with depression diagnosis' (n = 8853; self-reporting physician diagnosis of depression and experiencing depression in past 12 months) and respondents 'without depression diagnosis' (n = 30,478; no self-reported physician diagnosis of depression and not experiencing depression). Respondents with depression were further examined across depression severity based on Patient Health Questionnaire-9 (PHQ-9). Outcome measures included health-related quality-of-life (HRQoL; Medical Outcomes Study 36-item Short Form [SF-36v2]: mental and physical component summary [MCS and PCS]; Short-Form 6 Dimensions [SF-6D]; and EuroQol 5 Dimensions [EQ-5D]), work productivity and activity impairment (WPAI), and health resource utilization (HRU). Multivariate analysis was performed to examine group differences after adjusting covariates. Respondents with depression diagnosis reported significantly higher rates of diagnosed anxiety and sleep problems versus those without depression (for both; P < 0.001). Adjusted MCS, PCS, SF-6D, and EQ-5D scores were significantly lower in respondents with depression versus those without depression (all P < 0.001). Consistently, respondents with depression reported higher absenteeism, presenteeism, and overall WPAI, as well as greater number of provider visits, emergency room visits, and hospitalizations compared with those without depression (all P < 0.001). Further, burden of each outcome increased with an increase in disease severity. Diagnosed depression was associated with lower health-related quality-of-life and work productivity, and higher healthcare utilization than those without depression, and burden increased with an increase in symptom severity. The results show the burden of depression remains high even among those experiencing minimal symptoms.
Sections du résumé
BACKGROUND
Depression (major depressive disorder [MDD]) affects the functioning of patients in many facets of life. Very few large-scale studies to date have compared health and economic related outcomes of those with versus without depression, and across various depression severity groups. We aimed to evaluate humanistic and economic burden in respondents with and without depression diagnosis, and across symptom severity groups.
METHODS
Data from the 2017 US National Health and Wellness Survey (NHWS) were utilized. Of the adult respondents (N = 75,004), 59,786 were < 65 years old. Respondents not meeting eligibility criteria were excluded (e.g., those self-reporting bipolar disorder or experiencing depression in past 12 months but no depression diagnosis). Overall, data from 39,331 eligible respondents (aged 18-64 years) were analyzed; and comprised respondents 'with depression diagnosis' (n = 8853; self-reporting physician diagnosis of depression and experiencing depression in past 12 months) and respondents 'without depression diagnosis' (n = 30,478; no self-reported physician diagnosis of depression and not experiencing depression). Respondents with depression were further examined across depression severity based on Patient Health Questionnaire-9 (PHQ-9). Outcome measures included health-related quality-of-life (HRQoL; Medical Outcomes Study 36-item Short Form [SF-36v2]: mental and physical component summary [MCS and PCS]; Short-Form 6 Dimensions [SF-6D]; and EuroQol 5 Dimensions [EQ-5D]), work productivity and activity impairment (WPAI), and health resource utilization (HRU). Multivariate analysis was performed to examine group differences after adjusting covariates.
RESULTS
Respondents with depression diagnosis reported significantly higher rates of diagnosed anxiety and sleep problems versus those without depression (for both; P < 0.001). Adjusted MCS, PCS, SF-6D, and EQ-5D scores were significantly lower in respondents with depression versus those without depression (all P < 0.001). Consistently, respondents with depression reported higher absenteeism, presenteeism, and overall WPAI, as well as greater number of provider visits, emergency room visits, and hospitalizations compared with those without depression (all P < 0.001). Further, burden of each outcome increased with an increase in disease severity.
CONCLUSIONS
Diagnosed depression was associated with lower health-related quality-of-life and work productivity, and higher healthcare utilization than those without depression, and burden increased with an increase in symptom severity. The results show the burden of depression remains high even among those experiencing minimal symptoms.
Identifiants
pubmed: 35953786
doi: 10.1186/s12888-022-04165-x
pii: 10.1186/s12888-022-04165-x
pmc: PMC9367058
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
542Informations de copyright
© 2022. The Author(s).
Références
Arch Intern Med. 2006 May 22;166(10):1092-7
pubmed: 16717171
J Affect Disord. 2020 Dec 1;277:55-64
pubmed: 32799105
J Psychiatr Res. 2020 Jul;126:134-140
pubmed: 31439359
Int J Neuropsychopharmacol. 2018 Feb 1;21(2):128-144
pubmed: 29024974
Med Care. 2014 May;52(5):439-45
pubmed: 24714581
Health Econ. 2004 Sep;13(9):873-84
pubmed: 15362179
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
JAMA Psychiatry. 2018 Apr 1;75(4):336-346
pubmed: 29450462
J Occup Environ Med. 2015 Jan;57(1):105-10
pubmed: 25563547
J Med Econ. 2020 Sep;23(9):1032-1042
pubmed: 32468879
Ann Fam Med. 2010 Jul-Aug;8(4):348-53
pubmed: 20644190
J Affect Disord. 2017 Jun;215:299-313
pubmed: 28364701
J Pers Oriented Res. 2019 Dec 30;5(2):1-8
pubmed: 33569141
Expert Rev Pharmacoecon Outcomes Res. 2016 Jun;16(3):393-407
pubmed: 26495800
Actas Esp Psiquiatr. 2013 Sep-Oct;41(5):263-8
pubmed: 24096391
Ann Fam Med. 2011 Jul-Aug;9(4):305-11
pubmed: 21747101
Evid Based Ment Health. 2010 Aug;13(3):96
pubmed: 20682836
Soc Psychiatry Psychiatr Epidemiol. 2016 Nov;51(11):1525-1537
pubmed: 27667656
Acta Psychiatr Scand. 2015 Jan;131(1):51-60
pubmed: 24954156
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
J Affect Disord. 2010 Jan;120(1-3):126-32
pubmed: 19446342
Psychiatry Res. 2016 May 30;239:353-61
pubmed: 26908289
Psychiatry Res. 2018 Mar;261:547-553
pubmed: 29407721
Psychol Bull. 2017 Aug;143(8):783-822
pubmed: 28447828
Pharmacoeconomics. 2021 Jun;39(6):653-665
pubmed: 33950419
NCHS Data Brief. 2018 Feb;(303):1-8
pubmed: 29638213
Qual Life Res. 2013 Apr;22(3):585-96
pubmed: 22544416
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Value Health. 2011 Jun;14(4):475-82
pubmed: 21669372
Pharmacoeconomics. 1993 Nov;4(5):353-65
pubmed: 10146874
Pharmaceuticals (Basel). 2010 Aug 03;3(8):2426-2440
pubmed: 27713362
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Am J Manag Care. 2014 Aug 01;20(8):e294-301
pubmed: 25295792
Clinicoecon Outcomes Res. 2019 Mar 12;11:233-243
pubmed: 30881068
Neuropsychiatr Dis Treat. 2018 May 22;14:1339-1350
pubmed: 29872301
Harv Rev Psychiatry. 2011 Nov-Dec;19(6):277-89
pubmed: 22098324
Psychol Med. 2017 Feb;47(3):414-425
pubmed: 27780478
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941